Global Peripheral Intervention Drug-Eluting Devices Market Size By Type (Plain Old Balloon Angioplasty (POBA), Percutaneous Transluminal Angioplasty (PTA)), By Application (Drug-Eluting Balloons, Drug...

The Global Peripheral Intervention Drug-Eluting Devices Market was valued at USD 4.2 billion in 2023 and is projected to surpass USD 7.8 billion by 2031, growing at a CAGR of 7.9% during the forecast period from 2023 to 2031. The market is driven by the rising prevalence of peripheral arterial disease (PAD), advancements in drug-eluting stent (DES) and balloon technologies, and increasing preference for minimally invasive procedures in vascular interventions.

The adoption of drug-eluting technologies has significantly improved the efficacy of peripheral interventions by reducing restenosis rates, enhancing long-term patient outcomes, and minimizing repeat procedures. Additionally, the integration of biodegradable polymers and novel drug coatings is further fueling market expansion.

Drivers

Increasing Prevalence of Peripheral Arterial Disease (PAD)

Peripheral arterial disease (PAD) is becoming increasingly common due to factors such as aging populations, diabetes, obesity, and smoking habits. As PAD cases rise globally, the demand for effective, minimally invasive intervention devices has surged.

Advancements in Drug-Eluting Technologies

The development of next-generation drug-eluting stents and balloons with bioresorbable polymers and improved drug release mechanisms has enhanced procedural success rates, driving market growth.

Growing Preference for Minimally Invasive Procedures

Interventional cardiologists and vascular surgeons are increasingly adopting minimally invasive procedures over traditional surgical interventions due to reduced hospital stays, lower procedural risks, and faster recovery times, boosting the demand for drug-eluting devices.

Restraints

High Costs Associated with Drug-Eluting Devices

The high cost of drug-eluting stents and balloons remains a significant barrier, particularly in developing regions. Limited reimbursement policies in certain healthcare systems also hinder widespread adoption.

Regulatory Challenges and Approval Delays

The stringent regulatory landscape surrounding peripheral intervention devices can lead to lengthy approval processes, restricting the market entry of new innovations and delaying patient access to cutting-edge treatments.

Opportunity

Expansion in Emerging Markets

Rising healthcare expenditure and increasing awareness about vascular diseases in Asia-Pacific and Latin America are creating significant opportunities for market expansion.

Development of Biodegradable Drug-Eluting Stents

The emergence of biodegradable stents offers long-term benefits, including reduced late-stage thrombosis risks and elimination of permanent implants, opening new avenues for growth.

Technological Integration with AI & Robotics

The integration of robot-assisted intervention technologies and artificial intelligence (AI) for image-guided procedures is transforming peripheral interventions, improving precision, efficiency, and patient outcomes.

Market by System Type Insights

Based on system type, the Drug-Eluting Stents (DES) segment accounted for the largest market share in 2023. Drug-eluting stents are widely preferred due to their ability to prevent restenosis and improve vessel patency.

However, the Drug-Coated Balloons (DCB) segment is expected to witness the fastest growth during the forecast period, driven by the rising adoption of non-stent-based therapies that minimize the risk of permanent implants.

Market by End-Use Insights

By end-use, the Hospitals & Surgical Centers segment held the dominant market share in 2023, owing to the high volume of peripheral vascular procedures performed in hospital settings.

The Ambulatory Surgical Centers (ASCs) segment is projected to grow at a rapid pace due to the shift towards outpatient procedures, which offer lower costs and faster recovery times.

Market by Regional Insights

North America Leads the Market

North America accounted for the largest revenue share in 2023, supported by advanced healthcare infrastructure, high adoption of drug-eluting devices, and strong regulatory approvals.

Asia-Pacific Expected to Witness the Fastest Growth

The Asia-Pacific region is expected to grow at the highest CAGR, driven by rising healthcare investments, increasing PAD cases, and growing awareness of interventional therapies.

Europe Holds a Significant Market Share

Europe remains a key region, with strong reimbursement policies and leading medical device manufacturers driving innovation in the drug-eluting devices segment.

Competitive Scenario

Leading players in the Global Peripheral Intervention Drug-Eluting Devices Market include:

Medtronic plc

Boston Scientific Corporation

Abbott Laboratories

Cook Medical Inc.

Becton, Dickinson and Company (BD)

BIOTRONIK SE & Co. KG

Terumo Corporation

Cardinal Health

Meril Life Sciences Pvt. Ltd.

B. Braun Melsungen AG

Key Market Developments

2023 – Boston Scientific launched a next-generation drug-coated balloon with an enhanced drug delivery mechanism to reduce restenosis risk.

2024 – Medtronic plc received FDA approval for its biodegradable polymer drug-eluting stent, providing a resorbable alternative to traditional DES.

2025 – Abbott Laboratories announced a strategic partnership to develop AI-driven vascular imaging technology for enhanced precision in peripheral interventions.

Scope of Work – Global Peripheral Intervention Drug-Eluting Devices Market